Welcome to our dedicated page for REVELATION BIOSCIENCES SEC filings (Ticker: REVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVELATION BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVELATION BIOSCIENCES's regulatory disclosures and financial reporting.
Revelation Biosciences, Inc. insider filing shows its Chief Executive Officer and director, James Rolke, receiving a large equity grant. On 01/08/2026, he was awarded 532,829 shares of common stock at $0.90 per share, reported as an acquisition of non-derivative securities. These shares are described as Restricted Stock Units under the company’s 2021 Equity Incentive Plan, which vest quarterly over two years from the grant date.
Following this grant, Rolke is reported to beneficially own 933,489 shares of Revelation Biosciences common stock, held directly. The filing reflects routine equity compensation for a senior executive, with vesting tied to continued service over the two-year period.
Revelation Biosciences, Inc. Chief Financial Officer Chester S Zygmont III reported an indirect equity award through a family trust. On 01/08/2026, The Zygmont Family Trust received 78,145 shares of common stock as restricted stock units under the 2021 Equity Incentive Plan at $0.90 per share, vesting quarterly over two years from the grant date. Following this award, the trust indirectly held 473,790 shares of common stock for his benefit, with additional indirect holdings disclosed through Czeslaw Capital Fund, LLC.
Revelation Biosciences director Jennifer Carver reported an equity award of 41,981 shares of common stock on January 8, 2026. The filing shows these were granted at a stated price of $0.90 per share and are identified in a footnote as restricted stock units issued under the company’s 2021 Equity Incentive Plan. The award vests quarterly over one year from the grant date, meaning portions of the grant will settle into shares over four installments.
After this grant, Carver beneficially owns 57,669 shares of Revelation Biosciences common stock, all held directly. The filing reflects her status as a director of the company and indicates the transaction was reported by a single reporting person.
Revelation Biosciences director Jess Roper reported receiving an equity award of 41,981 shares of common stock on January 8, 2026 at a price of $0.90 per share. After this grant, Roper directly beneficially owns 57,667 shares of the company’s common stock.
The award is described as a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing also reflects an existing direct holding of 15,686 common shares, separate from the new restricted stock unit award.
Revelation Biosciences director Lakhmir S. Chawla reported an equity grant. On January 8, 2026, he acquired 41,981 shares of common stock at $0.90 per share, reported as an award under transaction code “A.” After this grant, he beneficially owned 57,667 shares of Revelation Biosciences common stock held directly.
The award represents a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing reflects his status as a director of Revelation Biosciences, Inc. (ticker REVB) and indicates this was a Form 4 filed for a single reporting person.
Revelation Biosciences (REVB) filed a Form S-8 to register 4,647,222 additional shares of common stock for issuance under its 2021 Equity Incentive Plan. The filing incorporates prior S-8 registrations by reference under General Instruction E. This expands the pool of shares available for equity awards to employees, directors, and consultants.
Revelation Biosciences (REVB) called a Special Meeting on December 3, 2025 to seek stockholder approval to reserve and issue common shares upon exercise of Class I Warrants in amounts that may exceed Nasdaq’s 20% Exchange Cap under Rule 5635(d). A second proposal would allow adjournment if more votes are needed.
The request follows a September 2025 warrant inducement in which holders exercised 13,065,000 Class H Warrants into 4,355,000 shares at $2.20 per share, and received 13,065,000 Class I Warrants (exercisable for five years from stockholder approval at $2.20). The Company reported gross proceeds of approximately $9.6 million from this transaction.
Key mechanics: record date is October 29, 2025 with 5,924,137 shares outstanding; quorum is 1,974,713 shares. Warrant holders will vote their shares in the same proportion as disinterested stockholders. If Proposal 1 is not approved, the Company cannot issue or agree to issue common stock or equivalents and must hold meetings every 60 days; prior adjournments added about $50,000 in costs.
Revelation Biosciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.
The release is included as Exhibit 99.1 under Item 2.02 and will not be treated as “filed” or incorporated by reference unless expressly stated.
Revelation Biosciences (REVB) reported Q3 2025 results, highlighting higher liquidity alongside a continued net loss and a going concern warning. Cash and cash equivalents were $12.7 million as of September 30, 2025, up from $6.5 million at year-end, supported by financing activity.
For the quarter, the company recorded a net loss of $1.91 million on operating expenses of $1.94 million (R&D $0.92 million; G&A $1.02 million). For the nine months, the net loss was $6.40 million. Stockholders’ equity rose to $11.0 million. The share count increased following two reverse stock splits in 2025 and subsequent warrant-related issuances.
Management disclosed that current cash is not expected to sustain operations within one year after issuance of the financial statements, indicating substantial doubt about continuing as a going concern. Financing events included the May 2025 public offering with net proceeds of $3.4 million and a September 2025 Class H warrant inducement generating net proceeds of $8.7 million. As of November 4, 2025, 5,924,137 shares were outstanding.
Revelation Biosciences (REVB) director reported an equity grant. On 10/29/2025, the insider acquired 15,625 shares of common stock (Code A) at $1.28 per share under the 2021 Equity Incentive Plan. The award vests 100% on January 28, 2026. Following the grant, the reporting person beneficially owned 15,686 shares, held directly.